Welcome to our dedicated page for UFP TECHNOLOGIES SEC filings (Ticker: UFPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on UFP TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into UFP TECHNOLOGIES's regulatory disclosures and financial reporting.
Daniel C. Croteau, a director of UFP Technologies, acquired 1,318 shares of common stock on 08/07/2025 at a reported price of $22.36 per share, increasing his direct beneficial ownership to 3,728 shares. The transaction corresponds to the exercise of a stock option with a $22.36 exercise price originally exercisable on 12/16/2015 and expiring on 12/16/2025. The Form 4 was signed by an attorney-in-fact on 08/14/2025.
UFP Technologies reported significant revenue and profit growth driven largely by recent acquisitions while facing margin pressure, higher interest expense, and customer concentration.
Net sales were $151.2 million for the quarter (up 37.2% year-over-year) and $299.3 million for the six months (up 39.1%). Net income was $17.2 million in the quarter and $34.4 million year-to-date, with diluted EPS of $2.21 for the quarter and $4.42 for six months. Gross margin declined to 28.8% in Q2 from 30.0% due to higher material, labor and onboarding inefficiencies at newly acquired AJR operations. SG&A rose in absolute dollars but decreased as a percentage of sales to 12.4% in Q2.
The company completed multiple acquisitions that expanded its medical-market capabilities and geography, including AJR Enterprises ($110.7M), AQF ($47.7M), Welch ($35.2M), Marble ($5.0M) and AJR Specialty ($2.8M); these collectively contributed about $76.3M in sales in H1 2025. Long-term debt outstanding was $163.6 million with Q2 interest expense of $2.7 million; cash from operations was $39.1 million for six months. Management disclosed contingent consideration obligations, tariff exposure estimated at ~$9 million annually, and customer concentration with two customers representing ~27.4% and ~20.3% of Q2 sales.